Why the study?
Hypertension remains the most common and strongest contributing factor to HFpEF, but traditional medications used for hypertension in patients with reduced ejection fraction have unclear benefits in HFpEF.
Design
Review
Authors
Loading...
May guide hypertension management in HFpEF; leaves open confirmation in prospective trials.
This review highlights the emerging role of ARNIs and SGLT2 inhibitors, as well as device-based therapies, in managing the complex nexus of hypertension and HFpEF.
Joury et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: